Dendritic cells promote CD8+ T cell responses under lymphopenic conditions [40], cross-present tumor-derived antigens [41] and expand in response to rIL-7 treatment [24], which promotes T-DC interactions [42]. The gene discussed is CD8A; the disease is neoplasm.